Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3281364 | 1.00 | MGLL (0.45) | MGLLEPHX2DGKAPRKCAPRKCE | |
| SCHEMBL19133947 | 0.99 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| SCHEMBL441410 | 0.99 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL421819 | 0.87 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL4074680 | 0.87 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Water SCHEMBL6549696 | 0.85 | MGLL (0.46) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL18209371 | 0.81 | DGKA (0.47) | MGLLEPHX2DGKAPRKCACNR2 | |
| Hydrochloric Acid SCHEMBL888280 | 0.81 | DGKA (0.47) | MGLLEPHX2DGKAPRKCACNR2 | |
| Hydrochloric Acid SCHEMBL25292894 | 0.80 | MGLL (0.43) | MGLLEPHX2DGKAPRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL6706588 | 0.80 | MGLL (0.43) | MGLLEPHX2DGKAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124584-A1 | DEGRADABLE CATIONIC LIPID CONTAINING DISULFIDE BOND AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| WO-2025124586-A1 | DEGRADABLE CATIONIC LIPID CONTAINING DISULFIDE BOND AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| US-20240226285-A9 | IMMUNOSTIMULATORY COMPOSITIONS | BAYER ANIMAL HEALTH GMBH (DE) | 2024-07-11 | — | — | US | claimed |
| US-20240131151-A1 | IMMUNOSTIMULATORY COMPOSITIONS | BAYER ANIMAL HEALTH GMBH (DE) | 2024-04-25 | — | — | US | claimed |
| CN-109689095-B | Increased fertility in bovine species | 拜耳动物保健有限责任公司 | 2023-10-03 | — | — | CN | claimed |
| US-11542507-B2 | Immunostimulatory compositions | BAYER ANIMAL HEALTH GMBH (DE) | 2023-01-03 | — | — | US | claimed |
| EP-3458083-B1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX INC (US) | 2022-11-02 | — | — | EP | claimed |
| US-11439703-B2 | Enhanced immune response in porcine species | ELANCO US, Inc. (US) | 2022-09-13 | — | — | US | claimed |
| CN-108712912-B | Enhanced immune response in aquatic species | 拜耳动物保健有限责任公司 | 2022-05-10 | — | — | CN | claimed |
| EP-3892260-A1 | IMMUNOSTIMULATORY COMPOSITIONS BASED ON LIPOSOMES WITH ZWITERIONIC AND CATIONIC LIPIDS | Bayer Animal Health GmbH (DE) | 2021-10-13 | — | — | EP | claimed |
| US-20180326049-A1 | ENHANCED IMMUNE RESPONSE IN PORCINE SPECIES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-11-15 | — | — | US | claimed |
| US-20180312842-A1 | Immunostimulatory Plasmids | ELANCO ANIMAL HEALTH GMBH (DE) | 2018-11-01 | — | — | US | claimed |
| WO-2017180917-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. (US) | 2017-10-19 | — | — | WO | claimed |
| US-9610254-B2 | Molecule mixture comprising an amphipathic molecule type A, which has a positive total charge in the hydrophilic range, and an amphipathic molecule type B and A polyphenol C, method for producing said molecule mixture and use thereof | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2017-04-04 | — | — | US | claimed |
| US-20150267201-A1 | IMMUNOSTIMULATORY PLASMIDS | BAYER ANIMAL HEALTH GMBH (DE) | 2015-09-24 | — | — | US | claimed |
| US-20150037398-A1 | MOLECULE MIXTURE COMPRISING AN AMPHIPATHIC MOLECULE TYPE A, WHICH HAS A POSITIVE TOTAL CHARGE IN THE HYDROPHILIC RANGE, AND AN AMPHIPATHIC MOLECULE TYPE B AND A POLYPHENOL C, METHOD FOR PRODUCING SAID MOLECULE MIXTURE AND USE THEREOF | Forschungszentrum Jülich GmbH (DE) | 2015-02-05 | — | — | US | claimed |
| WO-2010085514-A1 | FLUORESCENCE RESONANCE ENERGY TRANSFER ASSAYS FOR SARCO/ENDOPLASMIC RETICULUM CALCIUM ATPASE AND PHOSPHOLAMBAN | CELLADON CORPORATION (US) | 2010-07-29 | — | — | WO | claimed |
| US-20090042829-A1 | Nucleic Acid-Lipopolymer Compositions | CLSN LABORATORIES, INC. | 2009-02-12 | — | — | US | claimed |
| EP-0832270-B1 | CATIONIC LIPID:DNA COMPLEXES FOR GENE TARGETING | VALENTIS INC (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2001010413-A2 | PERIODIC STRUCTURES COMPRISING LIPIDS, POLYELECTROLYTES, AND STRUCTURES-INDUCING SOLUBLE OLIGOVALENT LINKERS | IDEA AG (DE) | 2001-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042829-A1 | Nucleic Acid-Lipopolymer Compositions | CETP, HDLBP, LIPA | MGLL 352/4885EPHX2 3766/4885DGKA 1170/4885 |
| US-11542507-B2 | Immunostimulatory compositions | TLR3, TLR9, TLR1 | MGLL 1380/4885EPHX2 3231/4885DGKA 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.